Protocol Ledger

NCT06604858 · Phase II · COMPLETED

Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer

Interventional Phase II clinical trial protocol NCT06604858 sponsored by MedSIR in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-29 Enrollment: 31 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06604858
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)31 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06604858
Protocol FieldVerified Registry Value
NCT IdentifierNCT06604858
Consolidated Lead SponsorMedSIR
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment31 participants (ACTUAL)
Registered Start Date2025-05-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06604858
Hospital Research SiteLocationSite Profile
Hospital Universitari Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->
Hospital Universitario Virgen del RocíoSeville, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI